Abstract: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in a fasted state is 400 ng/mL or less, is disclosed.

Abstract: This disclosure relates to a connection device that can provide a new function for an electronic device. A film antenna receives a wireless signal transmitted by radio, a relay unit relays the received wireless signal to a television receiver, an LED indicator emits light based on a control signal transmitted from the television receiver, a storage case stores the film antenna, the relay unit and a light emitting unit, and a connection member connects the storage case to the television receiver. In addition, in a state of being connected to the television receiver, in a normal direction to a housing surface having a display unit on a housing of the television receiver, the storage case has a protruding section which further protrudes from the housing surface and stores the film antenna in the protruding section. For example, this disclosure can be applied to a receiving device having a receiving unit which receives the wireless signal.

Abstract: The present disclosure relates to a light emitting device that can improve design of emitted light. A communication substrate is provided with an LED indicator which emits light. A light guiding plate has a concave surface portion which is a concave surface to cover the LED indicator, and receives the light from the LED indicator using the concave surface portion. A storage case stores the communication substrate and the light guiding plate in a state where a part of the light guiding plate is exposed. The light guiding plate allows the light from the LED indicator to penetrate to a part of the light guiding plate exposed from the storage case by diffusing the light received using the concave surface portion. For example, the present disclosure is applicable to the light emitting device that emits light using an LED or the like.

Abstract: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a dissolution rate of the drug from the composition is less than 85% after 30 minutes from the beginning of a dissolution test, is disclosed.

Abstract: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in a fasted state is 400 ng/mL or less, is disclosed.

Abstract: A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a dissolution rate of the drug from the composition is less than 85% after 30 minutes from the beginning of a dissolution test, is disclosed.

Abstract: A granular pharmaceutical composition for oral administration, comprising (1) atorvastatin or a pharmaceutically acceptable salt thereof, (2) a surfactant selected from the group consisting of sodium laurylsulfate and polyoxyethylene hydrogenated castor oil, and (3) a water-soluble polymer, is disclosed.

Abstract: A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 5 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed.

Abstract: A rapidly disintegrating tablet in the buccal cavity, comprising a drug, a treated starch having a degree of gelatinization of 30% to 60%, and a saccharide, and a process for manufacturing the same comprising the steps of mixing a drug, a treated starch having a degree of gelatinization of 30% to 60%, and a saccharide, and tabletting the mixture, are disclosed. The rapidly disintegrating tablet in the buccal cavity has a rapid disintegrability and solubility in the buccal cavity, and an appropriate hardness, without using special fillers, an apparatus, or the like.

Abstract: Cystatins that have been modified by glycosylation in order to enhance stability and activity are disclosed, as are methods of making such cystatins and methods of using such cystatins to inhibit proteolysis.

Abstract: Cystatins that have been modified by glycosylation in order to enhance stability and activity are disclosed, as are methods of making such cystatins and methods of using such cystatins to inhibit proteolysis.

Abstract: The present invention provides a surface mount Gull-Wing type resin-encapsulating package for encapsulating a semiconductor chip, wherein the cut face (outer tip end) of each outer lead is formed to have a smaller cross-sectional area than that of each outer lead, for improving the extension of solder to the cut face of that lead. Such relatively smaller cross-sectional area of the outer tip end of each outer lead reduces the exposed area of the lead material when disconnecting the leads from the frame in separating the device from the frame.